Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $125.6 million.

  • Zenas BioPharma's Total Liabilities rose 18545.13% to $125.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.6 million, marking a year-over-year increase of 18545.13%. This contributed to the annual value of $57.5 million for FY2024, which is 3125.64% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Total Liabilities is $125.6 million, which was up 18545.13% from $53.5 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Total Liabilities peaked at $288.8 million during Q2 2024, and registered a low of $43.8 million during Q4 2023.
  • Over the past 3 years, Zenas BioPharma's median Total Liabilities value was $57.5 million (recorded in 2024), while the average stood at $124.1 million.
  • Data for Zenas BioPharma's Total Liabilities shows a peak YoY increase of 18545.13% (in 2025) and a maximum YoY decrease of 8148.81% (in 2025) over the last 5 years.
  • Zenas BioPharma's Total Liabilities (Quarter) stood at $43.8 million in 2023, then surged by 31.26% to $57.5 million in 2024, then surged by 118.38% to $125.6 million in 2025.
  • Its Total Liabilities was $125.6 million in Q3 2025, compared to $53.5 million in Q2 2025 and $49.4 million in Q1 2025.